Alcohol & Antiretrovirals in HIV Infection, Oxidative Stress and Liver Disease

酒精

基本信息

  • 批准号:
    8278027
  • 负责人:
  • 金额:
    $ 44.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-09-30 至 2014-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Chronic alcohol consumption is associated with increased hepatic oxidative stress and reduced antioxidant defense resulting in alcohol-induced liver injury. Nucleoside reverse transcriptase inhibitors (NRTI) in combination with non-NRTIs and protease inhibitors have demonstrated their effectiveness as antiretroviral drugs against HIV-1 despite their well-described side-effects, including liver toxicity. While these side-effects are multi-factorial, oxidative stress and mitochondrial DNA damage has been suggested to play a key role. Mitochondrial DNA damage and increased oxidative stress produced by antiretroviral treatment (ART) may be aggravated by alcoholism, as chronic alcohol consumption is associated with increased hepatic oxidative stress and reduced antioxidant defense resulting in alcohol-induced liver injury. We propose to follow a cohort of 260 HIV infected ART naive participants, 65 patients who are being initiated on ART and are heavy alcohol users (Group 1), 65 patients who are being initiated on ART and do not drink alcohol or are moderate alcohol drinkers (Group 2), 65 patients who are early in HIV disease and are not being initiated on ART and are heavy alcohol users (Group 3), 65 patients who are early in HIV disease and are not being initiated on ART and do not drink alcohol or are moderate alcohol drinkers (Group 4), for 2 years. HIV staging (CD4 and viral load) co- morbidities, ART and other treatments will be documented. Questionnaires on demographics, BMI, food intake, and use of micronutrient supplements will be obtained and treated as covariates. ART will be restricted, and co-morbid conditions which are associated with oxidative stress, will be excluded before the baseline visit. Blood will be drawn for oxidative stress (malondialdehyde to indicate lipid peroxidation, protein carbonyls for protein oxidation, 8-hydroxyguanosine for DNA oxidation). Mitochondrial damage will be assessed with quantitative and qualitative changes in mitochondrial DNA content and with plasma lactate. Hepatocellular injury and function will be determined with plasma levels of ALT, AST, platelets, albumin, hyaluronic acid and total and conjugated bilirubin. Plasma antioxidants (glutathione, vitamins A and E, 1 and 2-carotenes, zinc and selenium) will also be determined. This proposal will determine the combined effects of chronic alcohol consumption and antiretroviral therapy on oxidative stress, antioxidant status, mitochondrial toxicity and liver dysfunction to provide the basis for potential preventive therapeutic approaches to protect the liver from alcohol and antiretroviral drug induced injury. PUBLIC HEALTH RELEVANCE: The objective of this proposal is to determine the combined effects of chronic alcohol consumption and antiretroviral therapy on oxidative stress, antioxidant status, mitochondrial toxicity and liver dysfunction, and to determine the effect of increased oxidative stress and nutritional deficiencies that might occur with chronic alcoholism on HIV-associated mitochondrial DNA damage. A better appreciation for alcohol's effects on HIV and liver disease may increase utilization of alcohol cessation interventions, thus improving treatment outcomes and providing the basis for potential preventive therapeutic approaches to protect liver from alcohol and antiretroviral drug-induced liver injury.
描述(由申请人提供):慢性饮酒与肝脏氧化应激增加和抗氧化防御降低有关,导致酒精性肝损伤。核苷逆转录酶抑制剂(NRTI)与非NRTI和蛋白酶抑制剂联合使用已证明它们作为抗HIV-1的抗逆转录病毒药物是有效的,尽管它们有很好的副作用,包括肝毒性。虽然这些副作用是多因素的,但氧化应激和线粒体DNA损伤被认为起着关键作用。抗逆转录病毒治疗(ART)产生的线粒体DNA损伤和氧化应激增加可能因酒精中毒而加重,因为慢性饮酒与肝脏氧化应激增加和抗氧化防御降低相关,导致酒精诱导的肝损伤。我们建议对260名初次接受抗逆转录病毒治疗的艾滋病毒感染者进行随访,其中65名患者正在开始接受抗逆转录病毒治疗,并且大量饮酒(第1组),65名患者正在开始接受抗逆转录病毒治疗,但不饮酒或适度饮酒(第2组),65名患者处于艾滋病毒早期,尚未开始接受抗逆转录病毒治疗,并且大量饮酒(第3组)。65名早期艾滋病毒患者,未开始抗逆转录病毒治疗,不饮酒或中度饮酒(第4组),为期2年。HIV分期(CD4和病毒载量)、合并症、ART和其他治疗将被记录。将获得有关人口统计、体重指数、食物摄入量和微量营养素补充剂使用情况的问卷,并将其作为协变量处理。抗逆转录病毒治疗将受到限制,与氧化应激相关的合并症将在基线访视前排除。抽血检测氧化应激(丙二醛检测脂质过氧化,蛋白质羰基检测蛋白质氧化,8-羟基鸟苷检测DNA氧化)。线粒体损伤将通过线粒体DNA含量和血浆乳酸的定量和定性变化来评估。肝细胞损伤和功能将通过血浆ALT、AST、血小板、白蛋白、透明质酸、总胆红素和结合胆红素水平来确定。血浆抗氧化剂(谷胱甘肽、维生素A和E、1和2-胡萝卜素、锌和硒)也将被测定。该建议将确定慢性饮酒和抗逆转录病毒治疗对氧化应激、抗氧化状态、线粒体毒性和肝功能障碍的综合影响,为潜在的预防性治疗方法提供基础,以保护肝脏免受酒精和抗逆转录病毒药物引起的损伤。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Marianna K Baum其他文献

P23-032-23 Associations Between Antidepressant Use and Fasting Blood Glucose Levels in People Living With and Without HIV
  • DOI:
    10.1016/j.cdnut.2023.100144
  • 发表时间:
    2023-07-01
  • 期刊:
  • 影响因子:
  • 作者:
    Stephanie Gieseken;Quingyun Liu;Marianna K Baum;Haley R Martin;Jupshy Jasmin;Angelique Johnson;Sabrina Sales Martínez;Leslie Seminario;Jose Bastida Rodriguez
  • 通讯作者:
    Jose Bastida Rodriguez

Marianna K Baum的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Marianna K Baum', 18)}}的其他基金

Community-Engaged Research on COVID-19 Testing Among Underserved and/or Vulnerable Populations Phase II
社区参与的针对服务不足和/或弱势群体的 COVID-19 检测研究第二阶段
  • 批准号:
    10544758
  • 财政年份:
    2022
  • 资助金额:
    $ 44.49万
  • 项目类别:
Community-Engaged Research on COVID-19 Testing Among Underserved and/or Vulnerable Populations Phase II
社区参与的针对服务不足和/或弱势群体的 COVID-19 检测研究第二阶段
  • 批准号:
    10447463
  • 财政年份:
    2022
  • 资助金额:
    $ 44.49万
  • 项目类别:
Cohort Studies on HIV/AIDS and Substance Abuse in Miami
迈阿密艾滋病毒/艾滋病和药物滥用队列研究
  • 批准号:
    9927614
  • 财政年份:
    2015
  • 资助金额:
    $ 44.49万
  • 项目类别:
Cohort Studies on HIV/AIDS and Substance Abuse in Miami
迈阿密艾滋病毒/艾滋病和药物滥用队列研究
  • 批准号:
    9144756
  • 财政年份:
    2015
  • 资助金额:
    $ 44.49万
  • 项目类别:
Cohort Studies on HIV/AIDS and Substance Abuse in Miami
迈阿密艾滋病毒/艾滋病和药物滥用队列研究
  • 批准号:
    9494556
  • 财政年份:
    2015
  • 资助金额:
    $ 44.49万
  • 项目类别:
Community-Engaged Research on COVID-19 Testing Among Underserved and/or Vulnerable Populations
社区参与的针对服务不足和/或弱势群体的 COVID-19 检测研究
  • 批准号:
    10662839
  • 财政年份:
    2015
  • 资助金额:
    $ 44.49万
  • 项目类别:
Alcohol & Antiretrovirals in HIV Infection, Oxidative Stress and Liver Disease
酒精
  • 批准号:
    7590839
  • 财政年份:
    2008
  • 资助金额:
    $ 44.49万
  • 项目类别:
Alcohol & Antiretrovirals in HIV Infection, Oxidative Stress and Liver Disease
酒精
  • 批准号:
    8080463
  • 财政年份:
    2008
  • 资助金额:
    $ 44.49万
  • 项目类别:
Alcohol & Antiretrovirals in HIV Infection, Oxidative Stress and Liver Disease
酒精
  • 批准号:
    7857921
  • 财政年份:
    2008
  • 资助金额:
    $ 44.49万
  • 项目类别:
Alcohol & Antiretrovirals in HIV Infection, Oxidative Stress and Liver Disease
酒精
  • 批准号:
    7691806
  • 财政年份:
    2008
  • 资助金额:
    $ 44.49万
  • 项目类别:

相似海外基金

6-thio-2'-deoxyguanosine in GBM: Evaluation of Pharmaco-dynamics, Effects of Prior Standard of Care and A Human Phase 0 Study
GBM 中的 6-硫代-2-脱氧鸟苷:药效学评估、先前护理标准的影响和人类 0 期研究
  • 批准号:
    10305569
  • 财政年份:
    2021
  • 资助金额:
    $ 44.49万
  • 项目类别:
6-thio-2'-deoxyguanosine in GBM: Evaluation of Pharmaco-dynamics, Effects of Prior Standard of Care and A Human Phase 0 Study
GBM 中的 6-硫代-2-脱氧鸟苷:药效学评估、先前护理标准的影响和人类 0 期研究
  • 批准号:
    10488244
  • 财政年份:
    2021
  • 资助金额:
    $ 44.49万
  • 项目类别:
6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification
GBM 中的 6-硫代-2-脱氧鸟苷:作用机制、功效和生物标志物鉴定的临床前评估
  • 批准号:
    10488242
  • 财政年份:
    2021
  • 资助金额:
    $ 44.49万
  • 项目类别:
6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma - A Duke and UTSW Collaboration
6-硫代-2-脱氧鸟苷:一种新型免疫原性端粒酶介导的胶质母细胞瘤疗法 - 杜克大学和 UTSW 合作
  • 批准号:
    10488237
  • 财政年份:
    2021
  • 资助金额:
    $ 44.49万
  • 项目类别:
6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma - A Duke and UTSW Collaboration
6-硫代-2-脱氧鸟苷:一种新型免疫原性端粒酶介导的胶质母细胞瘤疗法 - 杜克大学和 UTSW 合作
  • 批准号:
    10305565
  • 财政年份:
    2021
  • 资助金额:
    $ 44.49万
  • 项目类别:
6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification
GBM 中的 6-硫代-2-脱氧鸟苷:作用机制、功效和生物标志物鉴定的临床前评估
  • 批准号:
    10305568
  • 财政年份:
    2021
  • 资助金额:
    $ 44.49万
  • 项目类别:
RUI: Chemical Investigations into the Bioactivity of the DNA Lesion 8-Oxo-2'-deoxyguanosine
RUI:DNA 损伤 8-Oxo-2-脱氧鸟苷生物活性的化学研究
  • 批准号:
    1903855
  • 财政年份:
    2019
  • 资助金额:
    $ 44.49万
  • 项目类别:
    Standard Grant
Toxicity and Biosensing Properties of C8-Aryl-Deoxyguanosine Adducts
C8-芳基-脱氧鸟苷加合物的毒性和生物传感特性
  • 批准号:
    311600-2013
  • 财政年份:
    2017
  • 资助金额:
    $ 44.49万
  • 项目类别:
    Discovery Grants Program - Individual
Toxicity and Biosensing Properties of C8-Aryl-Deoxyguanosine Adducts
C8-芳基-脱氧鸟苷加合物的毒性和生物传感特性
  • 批准号:
    311600-2013
  • 财政年份:
    2015
  • 资助金额:
    $ 44.49万
  • 项目类别:
    Discovery Grants Program - Individual
Toxicity and Biosensing Properties of C8-Aryl-Deoxyguanosine Adducts
C8-芳基-脱氧鸟苷加合物的毒性和生物传感特性
  • 批准号:
    311600-2013
  • 财政年份:
    2014
  • 资助金额:
    $ 44.49万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了